Table 4.
Baseline characteristics of participants without and with prevalent diabetes at DHS
| Without prevalent DM |
With prevalent DM |
||
|---|---|---|---|
| Characteristics | (n=1869) | (n=187) | P value |
| Demographics | |||
| Age, years | 43.5±9.9 | 50.4±8.8 | <0.001 |
| Gender (male), % | 42.1 | 40.6 | 0.71 |
| Race | <0.001* | ||
| Hispanic | 13.9 | 15.4 | |
| Non-Hispanic black | 47.2 | 65.2 | |
| Non-H ispanic white | 37 | 17.1 | |
| BMI, kg/m2 | 29.9±7.2 | 35.9±8.2 | <0.001 |
| Comorbidities | |||
| Prevalent hypertension (%) | 33.7 | 72.2 | <0.001 |
| SBP, mm Hg | 125.8±17.6 | 136.9±17.3 | <0.001 |
| DBP, mm Hg | 78.8±9.9 | 81.5±9.1 | <0.001 |
| Current smoker, % | 25.8 | 25.7 | 0.95* |
| Current alcohol user, % | 73.4 | 51.4 | <0.001* |
| Medications | |||
| Diuretics, % | 7.3 | 26.2 | <0.001 |
| ACEI, % | 15.2 | 40.6 | <0.001 |
| ARB, % | 7.5 | 30 | <0.001 |
| Dietary supplements, % | 24.3 | 17.1 | 0.03 |
| Laboratory values | |||
| Magnesium, mg/dL | 2.08±0.17 | 1.96±0.20 | <0.001 |
| eGFR, mL/min/1.73m2 | 99.4±20.3 | 104.6±24.2 | 0.01 |
| ΔAeGFR, mL/min/1.73 m2 per year | −0.6 (−2.3, 0.7) | −2.0 (−3.8, −0.1) | <0.001 |
| Urine ACR, mg/g | 2.7 (1.8–4.3) | 3.4 (1.9–8.1) | <0.001 |
| Albumin, g/dL | 4.0±0.3 | 3.8±0.3 | <0.001 |
| Glucose, mg/dL | 91.9±11.7 | 185.9±80.3 | <0.001 |
| Calcium, mg/dL | 9.2±0.4 | 9.3±0.3 | 0.73 |
| Phosphate, mg/dL | 3.2±0.5 | 3.3±0.6 | 0.07 |
| Sodium, mEq/L | 137.8±2.3 | 136.5±2.8 | <0.001 |
| Potassium, mEq/L | 4.3±1.8 | 4.4±1.3 | 0.31 |
| Bicarbonate, mEq/L | 27.1±2.2 | 27.6±2.3 | 0.003 |
| iPTH, pg/mL | 37.3 (28.4, 49.6) | 34.6 (26.8, 51.2) | 0.19 |
| Total cholesterol, mg/dL | 180.1±36.8 | 186.5±45.8 | 0.17 |
| HDL, mg/dL | 50.8±14.8 | 46.6±12.8 | <0.001 |
| CRP, mg/L | 2.4 (1.0, 5.7) | 6.8 (2.4, 14.3) | <0.001 |
χ2 Data are presented as mean±SD, median (25th, 75th percentile) or per cent for categorical variables.
eGFR was calculated according to theMDRD study equation. Microalbuminuria was calculated as ACR. Dietary supplements consisted of any combination or single treatment with Mg, calcium, active vitamin D and/or multivitamins. Conversion factors for units: phosphate in mg/dL to mmol/L, ×0.3229; HDL in mg/dL to mmol/L, ×0.02586.
ACEI, ACE inhibitors; ACR, microalbumin/creatinine ratio; ARB, angiotensin II receptor blockers; BMI, body mass index; BP, blood pressure; CRP, C reactive protein; DHS, Dallas Heart Study; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; iPTH, intact parathyroid hormone.